Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Jitske van den Bulk (17142147) (author)
Бусад зохиолчид:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
-н: Jitske van den Bulk (17142147)
Хэвлэсэн: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
-н: Jitske van den Bulk (17142147)
Хэвлэсэн: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
-н: Jitske van den Bulk (17142147)
Хэвлэсэн: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
-н: Jitske van den Bulk (17142147)
Хэвлэсэн: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
-н: Caroline Robert (15032672)
Хэвлэсэн: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
-н: Hansol Lee (15054787)
Хэвлэсэн: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
-н: Joseph Toker (15399882)
Хэвлэсэн: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
-н: Ankita Mitra (17141783)
Хэвлэсэн: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
-н: Wei Liu (20030)
Хэвлэсэн: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
-н: Christine Pich-Bavastro (16509238)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
-н: Rohit Thummalapalli (17314483)
Хэвлэсэн: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
-н: Wei Liu (20030)
Хэвлэсэн: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
-н: Wei Liu (20030)
Хэвлэсэн: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
-н: Wei Liu (20030)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_9gn55g5iorjgn0ohdgdsadp7et